ISIS

Identification and targeting of somatic changes initiating sporadic cancers

Coordinatore	UNIVERSITAET REGENSBURG    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Germany [DE]
Totale costo	2˙499˙982 €
EC contributo	2˙499˙982 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2012-ADG_20120314
Funding Scheme	ERC-AG
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-03-01   -   2018-02-28

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITAET REGENSBURG  Organization address address: UNIVERSITAETSSTRASSE 31 city: REGENSBURG postcode: 93053 contact info Nome: Petra Cognome: Runge Email: send email Telefono: +49 941 943 5533 Fax: +49 941 943 3628	DE (REGENSBURG)	hostInstitution	2˙499˙982.14
2	UNIVERSITAET REGENSBURG  Organization address address: UNIVERSITAETSSTRASSE 31 city: REGENSBURG postcode: 93053 contact info Titolo: Prof. Nome: Christoph Cognome: Klein Email: send email Telefono: +49 941 944 6720 Fax: +49 941 944 6719	DE (REGENSBURG)	hostInstitution	2˙499˙982.14

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Cancer drugs are extremely ineffective, generally because current therapies do not address cellular heterogeneity. While hypothesis-driven research and functional genomics identify ever more novel putative therapeutic targets, the scientific community lacks rationales to attack the cellular heterogeneity in cancer, to select among the targets the most promising, and to design combination therapies. In particular, these all fail to provide successful adjuvant therapy settings after curative resection of the primary tumour before the onset of manifest metastasis. Here I propose a novel way to address cancer cell heterogeneity and to develop a rationale for the design of adjuvant therapies. The proposal rests upon the premises that (i) cancer initiation is causally associated with genetic changes, (ii) early, functionally relevant genetic changes -particularly involving DNA loss- have the highest probability to be shared among the progeny of a monoclonal, yet genetically unstable, cancer, and (iii) subsequent, cumulative genetic changes must either add to the fitness of the cell or at least be neutral to enable progression. The proposal is then built upon our observation that a subgroup of disseminated cancer cells (DCCs) displays normal karyotypes and DNA changes smaller than 10 Mb whilst primary tumours and more advanced DCCs harbour multiple additional chromosomal changes at the time of analysis. I suggest that although these karyotypically normal DCCs are the putative “loser cells” in cancer progression - since they are arrested in bone marrow - they are central to uncovering the early genetic changes of an individual cancer. With these cells we will identify for the first time the catalogue of initiating changes of sporadic cancers in a systematic way. We will then test the function of the early aberrations and perform functional viability screens to develop novel systemic therapies that target the Achilles’ heel of a given cancer: its shared critical alteration.'